COST-CONSEQUENCE OF CLADRIBINE TABLETS FOR THE TREATMENT OF HIGHLY-ACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) IN THE UK

被引：0

作者：

Miller, B. ^{[1
]}

Russel-Szymczyk, M. ^{[2
]}

Jensen, I. S. ^{[3
]}

Shah, A. ^{[1
]}

Alexopoulos, S. T. ^{[4
]}

Herbert, A. ^{[4
]}

McLean, T. ^{[4
]}

Tundia, N. ^{[5
]}

机构：

[1] Precis Hlth Econ & Outcomes Res, Grafton, MA USA

[2] Merck Sp Zoo, Affiliate Merck KGaA, Warsaw, Poland

[3] Precis Hlth Econ & Outcomes Res, Boston, MA USA

[4] Merck Serono Ltd, Affiliate Merck KGaA, Feltham, England

[5] EMD Serono Res & Dev Inst Inc, Affiliate Merck KGaA, Billerica, MA USA

来源：

VALUE IN HEALTH | 2023年 / 26卷 / 12期

关键词：

D O I：

暂无

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

EE658

引用

页码：S180 / S180

页数：1

共 50 条

[11] COST-EFFECTIVENESS ANALYSIS OF CLADRIBINE TABLETS FOR TREATMENT OF PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN BULGARIA [J].

Djambazov, S. ;

Slavchev, G. ;

Dineva, T. ;

Panayotov, P. ;

Vekov, T. .

VALUE IN HEALTH, 2018, 21 :S206-S206

[12] Cladribine Tablets for Relapsing-Remitting Multiple Sclerosis: A Clinician's Review [J].

Giovannoni, Gavin ;

Mathews, Joela .

NEUROLOGY AND THERAPY, 2022, 11 (02) :571-595

[13] Cost-consequence analysis of early vs. delayed natalizumab use in highly active relapsing-remitting multiple sclerosis: a simulation study [J].

Inojosa, Hernan ;

Schriefer, Dirk ;

Ness, Nils-Henning ;

Dillenseger, Anja ;

Akguen, Katja ;

Ziemssen, Tjalf .

JOURNAL OF NEUROLOGY, 2025, 272 (02)

[14] A BUDGET IMPACT ANALYSIS OF CLADRIBINE IN ENGLAND AND WALES FOR PATIENTS WITH HIGHLY ACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS (HA-RRMS) [J].

Herbert, A. ;

Ashton, L. ;

Alexopoulos, S. T. .

VALUE IN HEALTH, 2023, 26 (12) :S119-S119

[15] COST ANALYSIS OF SEVERAL TREATMENT SEQUENCES USED FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN PORTUGAL: THE CASE FOR CLADRIBINE TABLETS [J].

Silverio, N. ;

Goncalves, A. ;

Fonseca, A. .

VALUE IN HEALTH, 2017, 20 (09) :A721-A721

[16] Cladribine TabletsIn Relapsing-Remitting Multiple Sclerosis [J].

Victoria J. Muir ;

Greg L. Plosker .

CNS Drugs, 2011, 25 :239-249

[17] Efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis (RRMS) in the 120-week extension to the CLARITY study [J].

Giovannoni, Gavin ;

Comi, Giancarlo ;

Cook, Stuart ;

Rieckmann, Peter ;

Rammohan, Kottil ;

Soelberg-Soerensen, Per ;

Vermersch, Patrick ;

Martin, Emily ;

Dangond, Fernando .

MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (02) :NP6-NP7

[18] Investigation of cladribine treatment rules in subjects with relapsing-remitting multiple sclerosis (RRMS) by means of modelling & simulation [J].

Terranova, N. ;

Hicking, C. ;

Dangond, F. ;

Munafo, A. .

MULTIPLE SCLEROSIS JOURNAL, 2017, 23 :472-473

[19] An update on cladribine for relapsing-remitting multiple sclerosis [J].

Holmoy, Trygve ;

Torkildsen, Oivind ;

Myhr, Kjell-Morten .

EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (15) :1627-1635

[20] CLADRIBINE TABLETS (CT) VERSUS OTHER DISEASE-MODIFYING THERAPIES IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) - COST-EFFECTIVENESS ANALYSIS. [J].

Zieiba, P. ;

Pawlik, D. ;

Wieczorek, J. ;

Wojcik, R. ;

Kaczor, M. P. .

VALUE IN HEALTH, 2020, 23 :S632-S632

← 1 2 3 4 5 →